BRCA1 is altered in 5.04% of ovarian endometrioid tumor patients [2].

BRCA1 is an inclusion eligibility criterion in 2 clinical trials for ovarian endometrioid tumor, of which 2 are open and 0 are closed. Of the trials that contain BRCA1 status and ovarian endometrioid tumor as inclusion criteria, 1 is phase 2/phase 3 (1 open) and 1 is phase 3 (1 open) [3].

BRCA2 is altered in 6.12% of ovarian endometrioid tumor patients [2].

BRCA2 is an inclusion eligibility criterion in 2 clinical trials for ovarian endometrioid tumor, of which 2 are open and 0 are closed. Of the trials that contain BRCA2 status and ovarian endometrioid tumor as inclusion criteria, 1 is phase 2/phase 3 (1 open) and 1 is phase 3 (1 open) [3].

MLH1 is altered in 1.61% of ovarian endometrioid tumor patients [2].

MLH1 is an inclusion eligibility criterion in 1 clinical trial for ovarian endometrioid tumor, of which 1 is open and 0 are closed. Of the trial that contains MLH1 status and ovarian endometrioid tumor as inclusion criteria, 1 is phase 2 (1 open) [3].

MSH2 is altered in 3.86% of ovarian endometrioid tumor patients [2].

MSH2 is an inclusion eligibility criterion in 1 clinical trial for ovarian endometrioid tumor, of which 1 is open and 0 are closed. Of the trial that contains MSH2 status and ovarian endometrioid tumor as inclusion criteria, 1 is phase 2 (1 open) [3].

MSH6 is altered in 5.88% of ovarian endometrioid tumor patients [2].

MSH6 is an inclusion eligibility criterion in 1 clinical trial for ovarian endometrioid tumor, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and ovarian endometrioid tumor as inclusion criteria, 1 is phase 2 (1 open) [3].

PMS2 is altered in 1.37% of ovarian endometrioid tumor patients [2].

PMS2 is an inclusion eligibility criterion in 1 clinical trial for ovarian endometrioid tumor, of which 1 is open and 0 are closed. Of the trial that contains PMS2 status and ovarian endometrioid tumor as inclusion criteria, 1 is phase 2 (1 open) [3].